New Study Published in ESMO Open Highlights Guardant Reveal's Performance in Detecting Minimal Residual Disease in Patients with Early-Stage Breast Cancer
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced results from the LIBERATE study published in ESMO Open. The results in the peer-reviewed manuscript demonstrate the clinical validity and high performance of Guardant Reveal, the company's minimal residual disease (MRD) blood test, in predicting recurrence in patients with early-stage breast cancer. Guardant Reveal uses epigenomic (methylation) analysis to detect circulating tumor DNA (ctDNA) in a patient's blood without the need for a tissue sample.
The LIBERATE study retrospectively analyzed 290 blood samples from 95 patients who were diagnosed with early-stage ER+/HER2- or triple negative breast cancer undergoing chemotherapy prior to surgery, half of whom had localized disease with no lymph node involvement. Nearly 40% had minimal or no residual tumor by pathologic assessment following neoadjuvant chemotherapy.
Key findings include:
High Sensitivity and Specificity: Guardant Reveal demonstrated 100% sensitivity for distant recurrence in patients with ER+/HER2- breast cancer (which represents about 70% of all breast cancers), and 71% overall, with 100% specificity and 100% positive predictive value for relapse.
Significant Prognostic Power: Detection of ctDNA post-operatively was significantly prognostic for event-free survival (EFS), with median lead time of 152 days (range: 15-748 days) ahead of clinical recurrence (P < 0.0001).
Nearly 100% of All Samples Evaluable: All patients with post-operative blood samples had MRD results available from Reveal, highlighting the power of a tissue-free MRD test among patients receiving neoadjuvant therapy, particularly the large percentage who have minimal to no tumor found at surgery.
"This study underscores the clinical validity, robust prognostic value and high specificity of Guardant Reveal in identifying breast cancer patients at elevated risk of recurrence without the need for a tissue sample," said Craig Eagle, M.D., Guardant Health chief medical officer. "These findings reinforce the critical role Reveal can achieve in clinical decision-making, potentially transforming neoadjuvant and post-treatment surveillance strategies and improving patient outcomes."
This publication adds to the growing body of evidence of Reveal's strong performance in early-stage breast cancer. Earlier this year, a peer-reviewed publication in Clinical Cancer Research focused on stage II and III triple negative breast cancer demonstrated 83% sensitivity for metastatic recurrence and 99.5% sample-level specificity. Post-surgical ctDNA detection was prognostic for shorter recurrence-free interval (P < 0.0001). Additionally, ctDNA detection at the post-neoadjuvant, presurgical time point was associated with a shorter recurrence-free interval in patients with residual disease at surgery (P < 0.0001).
The full manuscript in ESMO Open is available here.
About Guardant Health
Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care and accelerating new cancer therapies by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and treatment selection for patients with advanced cancer. For more information, visit guardanthealth.com and follow the company on LinkedIn, X (Twitter) and Facebook.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding the potential utilities, values, benefits and advantages of Guardant Health's liquid biopsy tests or assays, which involve risks and uncertainties that could cause the actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors. These and additional risks and uncertainties that could affect Guardant Health's financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions 'Risk Factors' and 'Management's Discussion and Analysis of Financial Condition and Results of Operation' and elsewhere in its Annual Report on Form 10-K for the year ended December 31, 2024, and in its other reports filed with or furnished to the Securities and Exchange Commission thereafter. The forward-looking statements in this press release are based on information available to Guardant Health as of the date hereof, and Guardant Health disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Guardant Health's views as of any date subsequent to the date of this press release.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CNBC
35 minutes ago
- CNBC
Bitcoin sinks below $99,000 as U.S. strikes on Iran trigger crypto market sell-off
Bitcoin fell to its lowest level since May over the weekend, as rising tensions in the Middle East and renewed inflation fears triggered a sharp selloff across digital assets. Bitcoin dropped below the $99,000 mark on Sunday — its lowest point in more than a month — as the crypto market became the first to react to escalating geopolitical risk. Bitcoin is trading around $99,380, down more than 2% over the past 24 hours, while ether has dropped 5% to below $2,200. Solana, XRP, and dogecoin also posted sharp losses, dragging the entire crypto complex deep into the red. The selloff appears to be a combination of geopolitical shock and macroeconomic concern. Iran has reportedly threatened to block the Strait of Hormuz — a vital shipping lane that handles about 20% of global oil supply. JPMorgan warns that a full closure could drive oil prices as high as $130 per barrel. One prominent macro research firm notes that such a spike could send U.S. inflation back toward 5% — a level not seen since March 2023, when the Fed was still actively raising rates. That outlook has traders reassessing the path of interest rates — and rotating out of speculative assets like crypto. While bitcoin is often pitched as an inflation hedge, it's currently behaving more like a high-beta tech stock. According to crypto data provider Kaiko, bitcoin's correlation with the tech-heavy Nasdaq has climbed sharply in recent weeks, after hitting a multi-month low earlier this year — a period that coincided with surging inflows into spot bitcoin ETFs. Institutional positioning also appears to have shifted. More than $1.04 billion flowed into spot bitcoin ETFs from Monday through Wednesday last week, according to data from CoinGlass. But those inflows collapsed heading into the weekend, with zero net movement Thursday and just $6.4 million on Friday — coinciding with President Donald Trump's early G7 departure and the announcement of a two-week review of U.S. options on Iran. The technical breakdown added fuel to the selloff. CoinGlass research shows bitcoin's drop below $99,000 triggered forced selling across offshore derivatives platforms like Binance and Bybit. At its peak on Sunday, more than $1 billion in crypto positions were liquidated during a 24-hour span — with over 95% coming from long bets, underscoring just how overexposed the market was heading into the weekend.
Business Wire
an hour ago
- Business Wire
New Data Show Delve Bio's Metagenomic Testing Delivers Broader, Deeper Pathogen Identification Compared to Traditional Testing
BOSTON--(BUSINESS WIRE)-- Delve Bio, a pioneer in metagenomic next-generation sequencing (mNGS) for infectious diseases, today announced data presented at the American Society for Microbiology (ASM) Microbe conference in Los Angeles showing the impact of metagenomic sequencing for transforming infectious disease diagnostics by offering advances compared to traditional microbiological testing. "Delve Bio's metagenomic sequencing technology enables clinicians to identify the cause of serious central nervous system infections when existing methods do not and speed is critical' said Brad Murray, chief executive officer of Delve Bio. Among the data presented at the meeting is a comparison of Delve's metagenomic cerebrospinal fluid (CSF) test, Delve Detect CSF, compared to a traditional PCR-based meningitis/encephalitis (ME) panel. The study reanalyzed samples from a diverse patient cohort previously tested using the ME panel. The data showed that mNGS can be used in conjunction with microbiological testing to increase diagnostic yield by identifying pathogens that are not detectable with traditional, pathogen-specific panel testing. The inclusion of mNGS tests like Delve Detect, which has a 48-hour turnaround time, can shorten time to diagnosis, enabling clinicians to initiate targeted therapies sooner. 'This study showed substantial agreement between Delve Detect and a syndromic PCR panel. But importantly, Delve Detect also identified pathogens that were not included on the PCR panel and would have been missed as causes of a patient's infection if mNGS were not included in the diagnostic workup,' said Benjamin Bradley, M.D., Ph.D., medical director of virology and molecular infectious diseases at ARUP Laboratories. 'This study supports including mNGS in the diagnostic workup for patients with complex central nervous system infections.' The study included 122 samples — 47 positive and 75 negative. Analysis showed that in comparison with the ME panel, Delve Detect CSF demonstrated approximately 10% higher positivity rate (48% vs. 38%), with an additive diagnostic yield of 24%. This added yield included detection of multiple co-infections, 16 unique organisms not included in the ME panel, and positive detections in 19 samples (25%) that were negative by the ME panel. Additionally, in samples that were negative by both tests, Delve Detect CSF showed high agreement (95%) with the ME panel, supporting the negative predictive value of mNGS. The company's full presence at ASM Microbe 2025 includes: Delve's chief medical officer Steve Miller, M.D., Ph.D. hosted A New Era: Metagenomic Sequencing for Comprehensive Pathogen Detection, exploring real world evidence, clinical cases and considerations for laboratory teams implementing mNGS. Presentation of a case report in a feature poster, Using Metagenomic Sequencing to Diagnose a Novel Moraxella CNS Shunt Infection in a Culture-Negative Case Presentation of data comparing the company's mNGS CSF test, Delve Detect, to a widely used, PCR meningitis/encephalitis panel as part of the session Assessing the Clinical Impact of Next-Generation Sequencing: Where Are We Now? 'These presentations at ASM highlight the transformation underway in infectious disease diagnostics. Delve Bio's metagenomic sequencing technology enables clinicians to identify the cause of serious central nervous system infections when existing methods do not deliver a diagnosis and speed is critical,' said Brad Murray, chief executive officer of Delve Bio. 'We're working to make this technology more widely available to neurologists, infectious disease physicians and laboratory teams so they can get patients the answers they need.' Conference attendees are also invited to visit Delve Bio at booth #1440 to learn more about the company's metagenomic platform, including Delve Detect and its proprietary bioinformatics platform Delve Decide. Delve Detect is Delve Bio's flagship metagenomic testing service, providing comprehensive pathogen detection with a 48-hour turnaround time after sample receipt and including access to Delve's Clinical Microbial Sequencing Board, an on-call team of infectious disease experts who review results in clinical context. About Delve Bio, Inc. Delve Bio is a metagenomic next-generation sequencing (mNGS) company that empowers laboratories and clinicians with the insights they need to confidently diagnose routine and rare infectious diseases, thereby minimizing the impact of harmful pathogens on humanity. By leveraging its unbiased, pathogen-agnostic mNGS platform, Delve Bio is able to identify a wide range of pathogens with a single test. Founded by world leaders in genomics and infectious disease Drs. Charles Chiu, Joe DeRisi, Michael Wilson, Pardis Sabeti, and Matthew Meyerson, the company is backed by top institutional investors including Perceptive Xontogeny Venture Fund II, Section 32, and GV, along with leading individual investors. For more information, visit
Business Wire
an hour ago
- Business Wire
Tigo Energy and BayWa r.e. Empower High-Wattage C&I Solar in Thailand
CAMPBELL, Calif.--(BUSINESS WIRE)-- Tigo Energy, Inc. (NASDAQ: TYGO) ('Tigo' or 'Company'), a leading provider of intelligent solar and energy software solutions, today announced that the Company will share a trade show booth with BayWa r.e. at the annual ASEAN Sustainable Energy Week 2025, from July 2-4, at the QSNCC in Bangkok, Thailand. At the show, Tigo will focus on supporting Commercial and Industrial (C&I) solar installers and engineering, procurement, and construction specialists (EPCs) as enforcement of new rapid shutdown requirements begins, deploying high-wattage modules in high-irradiance regions, and ensuring Total Quality Solar (TQS) through Tigo service programs. For solar projects in hot, humid, and high-irradiance (>1000W/m 2) regions like Southeast Asia, the Tigo TS4-X family of MLPE devices provides the latest in optimization, monitoring, and safety for solar installers deploying high-wattage modules, including supporting the increased backside gains of modern bifacial modules. The TS4-X product line gives installers more freedom to deploy the modules that deliver the power and performance for their customer deployments, reduce labor costs with a no-bolt design and no need for additional ground wiring, and contribute to improving Levelized Cost Of Energy (LCOE) in the large-scale solar sector. Tigo MLPE devices pair with an industry-leading list of third-party solar inverters to deliver design and installation flexibility for solar installers and EPCs. 'Thailand's rooftop solar market is growing rapidly and so is the demand for safer, smarter systems,' said Junrhey Castro, managing director at BayWa r.e. Solar Systems. 'As a regional distributor, we're committed to supporting this growth with reliable solutions that protect both the performance and investment of our customers. Having Tigo in our product portfolio reflects our focus on quality and innovation for solar professionals across Thailand and Southeast Asia.' In Thailand, Tigo will also invite installers to enroll directly in the Tigo Green Glove service program at the BayWa r.e. booth. The Green Glove service program is a premium support experience for installers of commercial and industrial (C&I) systems that enhances the installer experience and drives quality across the solar value chain with a process that includes a set of formalized support engagements for Tigo C&I installers before, during, and after the installation. 'Strong collaboration between global companies like BayWa r.e. and Tigo is part of what makes the solar ecosystem work for more installers and EPCs around the world,' said Jing Tian, chief growth and revenue officer at Tigo Energy. 'As with many of the pro-solar nations in Asia, we believe that products like the TS4-X and programs like Green Glove make great strides in further driving LCOE down, and Total Quality Solar up, respectively. In regions with higher-than-normal irradiance values in particular, these dynamics benefit the entire industry, from equipment manufacturer to installer, and on to the operators and asset owners.' ASEAN Sustainable Energy Week 2025 attendees are invited to visit BayWa r.e. and Tigo at booth F11 from July 2-4, at the QSNCC in Bangkok, Thailand. To book an appointment with a Tigo specialist at the show, please register your interest here. About Tigo Energy Founded in 2007, Tigo Energy, Inc. (NASDAQ: TYGO) is a worldwide leader in the development and provider of smart hardware and software solutions that enhance safety, increase energy yield, and lower operating costs of residential, commercial, and utility-scale solar systems. Tigo combines its Flex MLPE (Module Level Power Electronics) and solar optimizer technology with intelligent, cloud-based software capabilities for advanced energy monitoring and control. Tigo MLPE products maximize performance, enable real-time energy monitoring, and provide code-required rapid shutdown at the module level. The company also develops and provides products such as inverters and battery storage systems for the residential solar-plus-storage market. For more information, please visit
